231 related articles for article (PubMed ID: 29194902)
1. Metastatic prostate cancer incidence in Australia after amendment to prostate-specific antigen screening guidelines.
Smith S; Wolanski P
ANZ J Surg; 2018; 88(7-8):E589-E593. PubMed ID: 29194902
[TBL] [Abstract][Full Text] [Related]
2. US Preventive Services Task Force prostate-specific antigen screening guidelines result in higher Gleason score diagnoses.
Gejerman G; Ciccone P; Goldstein M; Lanteri V; Schlecker B; Sanzone J; Esposito M; Rome S; Ciccone M; Margolis E; Simon R; Guo Y; Pentakota SR; Sadeghi-Nejad H
Investig Clin Urol; 2017 Nov; 58(6):423-428. PubMed ID: 29124241
[TBL] [Abstract][Full Text] [Related]
3. Past, Current, and Future Incidence Rates and Burden of Metastatic Prostate Cancer in the United States.
Kelly SP; Anderson WF; Rosenberg PS; Cook MB
Eur Urol Focus; 2018 Jan; 4(1):121-127. PubMed ID: 29162421
[TBL] [Abstract][Full Text] [Related]
4. Impact of the 2012 United States Preventive Services Task Force statement on prostate-specific antigen screening: analysis of urologic and primary care practices.
Perez TY; Danzig MR; Ghandour RA; Badani KK; Benson MC; McKiernan JM
Urology; 2015 Jan; 85(1):85-9. PubMed ID: 25440819
[TBL] [Abstract][Full Text] [Related]
5. Impact of the U.S. Preventive Services Task Force recommendations against prostate specific antigen screening on prostate biopsy and cancer detection rates.
Bhindi B; Mamdani M; Kulkarni GS; Finelli A; Hamilton RJ; Trachtenberg J; Zlotta AR; Evans A; van der Kwast TH; Toi A; Fleshner NE
J Urol; 2015 May; 193(5):1519-24. PubMed ID: 25481037
[TBL] [Abstract][Full Text] [Related]
6. Impact of Prostate-specific Antigen (PSA) Screening Trials and Revised PSA Screening Guidelines on Rates of Prostate Biopsy and Postbiopsy Complications.
Gershman B; Van Houten HK; Herrin J; Moreira DM; Kim SP; Shah ND; Karnes RJ
Eur Urol; 2017 Jan; 71(1):55-65. PubMed ID: 26995328
[TBL] [Abstract][Full Text] [Related]
7. Effect of the USPSTF Grade D Recommendation against Screening for Prostate Cancer on Incident Prostate Cancer Diagnoses in the United States.
Barocas DA; Mallin K; Graves AJ; Penson DF; Palis B; Winchester DP; Chang SS
J Urol; 2015 Dec; 194(6):1587-93. PubMed ID: 26087383
[TBL] [Abstract][Full Text] [Related]
8. Prostate cancer incidence across stage, NCCN risk groups, and age before and after USPSTF Grade D recommendations against prostate-specific antigen screening in 2012.
Butler SS; Muralidhar V; Zhao SG; Sanford NN; Franco I; Fullerton ZH; Chavez J; D'Amico AV; Feng FY; Rebbeck TR; Nguyen PL; Mahal BA
Cancer; 2020 Feb; 126(4):717-724. PubMed ID: 31794057
[TBL] [Abstract][Full Text] [Related]
9. Prostate Needle Biopsy Outcomes in the Era of the U.S. Preventive Services Task Force Recommendation against Prostate Specific Antigen Based Screening.
Banerji JS; Wolff EM; Massman JD; Odem-Davis K; Porter CR; Corman JM
J Urol; 2016 Jan; 195(1):66-73. PubMed ID: 26254722
[TBL] [Abstract][Full Text] [Related]
10. PSA screening, prostate biopsy, and treatment of prostate cancer in the years surrounding the USPSTF recommendation against prostate cancer screening.
Kearns JT; Holt SK; Wright JL; Lin DW; Lange PH; Gore JL
Cancer; 2018 Jul; 124(13):2733-2739. PubMed ID: 29781117
[TBL] [Abstract][Full Text] [Related]
11. Establishing the pathways and indications for performing isotope bone scans in newly diagnosed intermediate-risk localised prostate cancer - results from a large contemporaneous cohort.
KandaSwamy GV; Bennett A; Narahari K; Hughes O; Rees J; Kynaston H
BJU Int; 2017 Nov; 120(5B):E59-E63. PubMed ID: 28317247
[TBL] [Abstract][Full Text] [Related]
12. Increase in the Annual Rate of Newly Diagnosed Metastatic Prostate Cancer: A Contemporary Analysis of the Surveillance, Epidemiology and End Results Database.
Bandini M; Mazzone E; Preisser F; Nazzani S; Zaffuto E; Marchioni M; Tian Z; Pompe RS; Tilki D; Graefen M; Shariat SF; Montorsi F; Saad F; Briganti A; Karakiewicz P
Eur Urol Oncol; 2018 Sep; 1(4):314-320. PubMed ID: 31100253
[TBL] [Abstract][Full Text] [Related]
13. Changes observed in prostate biopsy practices in an inner city hospital with a high risk patient population following the 2012 uspstf psa screening recommendations.
Tam AW; Khusid J; Inoyatov I; Becerra AZ; Davila J; Chouhan JD; Weiss JP; Hyacinthe LM; McNeil BK; Winer AG
Int Braz J Urol; 2018; 44(4):697-703. PubMed ID: 29617073
[TBL] [Abstract][Full Text] [Related]
14. Changes in the outcome of prostate biopsies after preventive task force recommendation against prostate-specific antigen screening.
Zakaria AS; Dragomir A; Brimo F; Kassouf W; Tanguay S; Aprikian A
BMC Urol; 2018 Aug; 18(1):69. PubMed ID: 30126402
[TBL] [Abstract][Full Text] [Related]
15. Impact of the United States Preventive Services Task Force 'D' recommendation on prostate cancer screening and staging.
Eapen RS; Herlemann A; Washington SL; Cooperberg MR
Curr Opin Urol; 2017 May; 27(3):205-209. PubMed ID: 28221220
[TBL] [Abstract][Full Text] [Related]
16. Trends for Stage and Grade Group of Prostate Cancer in the US (2010-2016).
Schmanke K; Okut H; Ablah E
Urology; 2021 Mar; 149():110-116. PubMed ID: 33227304
[TBL] [Abstract][Full Text] [Related]
17. Change in prostate cancer presentation coinciding with USPSTF screening recommendations at a community-based urology practice.
Gaylis FD; Choi JE; Hamilton Z; Dato P; Cohen E; Calabrese R; Prime H; Rosenbaum A; Kader AK
Urol Oncol; 2017 Nov; 35(11):663.e1-663.e7. PubMed ID: 28736250
[TBL] [Abstract][Full Text] [Related]
18. Long-term consequences of the USPSTF Grade D recommendation for prostate-specific antigen screening.
Joshi SS; Filson CP
Cancer; 2020 Feb; 126(4):694-696. PubMed ID: 31794066
[No Abstract] [Full Text] [Related]
19. Effects of the 2012 and 2018 US preventive services task force prostate cancer screening guidelines on pathologic outcomes after prostatectomy.
Plambeck BD; Wang LL; Mcgirr S; Jiang J; Van Leeuwen BJ; Lagrange CA; Boyle SL
Prostate; 2022 Feb; 82(2):216-220. PubMed ID: 34807485
[TBL] [Abstract][Full Text] [Related]
20. The impact of the United States Preventive Services Task Force (USPTSTF) recommendations against prostate-specific antigen (PSA) testing on PSA testing in Australia.
Zargar H; van den Bergh R; Moon D; Lawrentschuk N; Costello A; Murphy D
BJU Int; 2017 Jan; 119(1):110-115. PubMed ID: 27454454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
